KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Return on Equity (2016 - 2025)

NovoCure's Return on Equity history spans 11 years, with the latest figure at 0.4% for Q4 2025.

  • For Q4 2025, Return on Equity rose 7.0% year-over-year to 0.4%; the TTM value through Dec 2025 reached 0.4%, up 7.0%, while the annual FY2025 figure was 0.39%, 8.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.4% at NovoCure, up from 0.51% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.03% in Q1 2021 and bottomed at 0.55% in Q4 2023.
  • The 5-year median for Return on Equity is 0.41% (2023), against an average of 0.32%.
  • The largest annual shift saw Return on Equity crashed -34bps in 2023 before it rose 8bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.14% in 2021, then tumbled by -47bps to 0.21% in 2022, then tumbled by -162bps to 0.55% in 2023, then grew by 15bps to 0.47% in 2024, then increased by 15bps to 0.4% in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Return on Equity are 0.4% (Q4 2025), 0.51% (Q3 2025), and 0.48% (Q2 2025).